Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 62 Gastrointestinal 33 Genitourinary 24 Head & Neck 18 Breast 17 Gynecologic 16 Lymphoid 9 Other solid neoplasm 8 Sarcoma 6 Plasma cell 4 Tumor-Agnostic 3 Other hematologic neoplasm 3 Endocrine 3 CNS 3 Dermatologic 2 NET 1 Myeloid 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 18 lanreotide 7 Octreotide 7 pembrolizumab 6 Sunitinib 6 Magnetic Resonance Spectroscopy 5 lutetium Lu 177 dotatate 4 gallium Ga 68 dotatate 4 cabozantinib 4 Nivolumab 4 Carboplatin 4 telotristat ethyl 3 pasireotide 3 lenvatinib 3 arginyllysine 3 Temozolomide 3 Specimen Handling 3 Etoposide 3 Erlotinib Hydrochloride 3 Bevacizumab 3 surufatinib 2 pazopanib 2 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Sorafenib 2 Phantoms, Imaging 2 Paclitaxel 2 Oxaliplatin 2 Ipilimumab 2 Doxorubicin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × durvalumab × NET × Clear all

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡